It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Demand normalisation post the second wave contributed to the steady growth
It plays a pivotal role in monitoring pharmaceutical pricing
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company has strong product launches both in India and overseas
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Subscribe To Our Newsletter & Stay Updated
